EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.

EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.

Squamous cell carcinomas (SCC) account for approximately 30% of non-small cell lung cancer (NSCLC). Current staging methods do not adequately predict outcome for this disease. EMX2 is a homeo-domain containing transcription factor known to regulate a key developmental pathway. This study assessed th...

Full description

Bibliographic Details
Main Authors: Dongsheng Yue, Hui Li, Juanjuan Che, Yi Zhang, Bhairavi Tolani, Minli Mo, Hua Zhang, Qingfeng Zheng, Yue Yang, Runfen Cheng, Joy Q Jin, Thomas W Luh, Cathryn Yang, Hsin-Hui K Tseng, Etienne Giroux-Leprieur, Gavitt A Woodard, Xishan Hao, Changli Wang, David M Jablons, Biao He
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4488446?pdf=render

Internet

http://europepmc.org/articles/PMC4488446?pdf=render

Similar Items